Abstract:Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Immunogenetic analysis indicated that m366.6 is a germline-like mAb with very few somatic mutations from the closest VH and V lambda germline genes. Importantly, we demonstrated that it potently neutralized DENV both in vitro and in the mouse models of DENV infection without detectable antibody-dependent enhancement (ADE) effect. The epitope of m366.6 was mapped to the highly conserved regions on DIII, which may guide the design of effective dengue vaccine immunogens. Furthermore, as the first germline-like mAb derived from a naive antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate. Author summary Dengue virus infects 50-100 million people each year. Infection is initiated by entry of the virus into cells mediated by the viral envelope glycoproteins. There are four closely related DENV serotypes, but they all are antigenically distinct, with each comprising several genotypes that exhibit differences in their infection characteristics in both the mosquito vector and in the human host. One of the confounding problems that has faced vaccine and biological drugs development for decades is the inability of antibodies to one serotype to protect against infection by another one. Instead, the induced humoral immune response to one dengue virus infection can enhance the infection and disease processes brought by a subsequent infection with another dengue serotype. In this study, by using a competitive sorting strategy to interrogate a human naive antibody library, we identified a cross-reactive mAb, designated as m366.6, against the four DENV serotypes. The mAb m366.6 possesses only few somatic mutations from the closest VH and V lambda germline genes and high affinity to DIII. Most importantly, the germline-like m366.6 demonstrated a broad spectrum of neutralization against the four DENV serotypes. Thus, m366.6 is a promising candidate therapeutics and its epitope may imply on the design of effective vaccine immunogens to elicit m366.6-like antibodies in vivo.

Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Structural basis of Chikungunya virus inhibition by monoclonal antibodies

Structural Analyses at Pseudo Atomic Resolution of Chikungunya Virus and Antibodies Show Mechanisms of Neutralization

Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region

A Small Antigenic Determinant of the Chikungunya Virus E2 Protein Is Sufficient to Induce Neutralizing Antibodies which Are Partially Protective in Mice

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

Deep mutationally scanned (DMS) CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies

Highly Potent Multivalent VHH Antibodies Against Chikungunya Isolated from an Alpaca Naïve Phage Display Library.

Expression of anti-chikungunya single-domain antibodies in transgenic Aedes aegypti reduces vector competence for chikungunya virus and Mayaro virus

A Non-Ace2 Competing Human Single-Domain Antibody Confers Broad Neutralization Against SARS-CoV-2 and Circulating Variants.

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection

Additional File 2 of Highly Potent Multivalent VHH Antibodies Against Chikungunya Isolated from an Alpaca Naïve Phage Display Library

Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS‐CoV‐2

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Promising application of monoclonal antibody against chikungunya virus E1-antigen across genotypes in immunochromatographic rapid diagnostic tests

A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening